Navigation Links
Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
Date:1/12/2009

CAMBRIDGE, Mass., Jan. 12 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced that it has initiated a proof-of-concept study of IDX184, a liver-targeted nucleotide prodrug candidate for the treatment of HCV under an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA). The study is evaluating IDX184 in treatment-naive hepatitis C genotype-1 infected patients.

"We are very pleased with the progress that we have made in our hepatitis C discovery program in 2008, having successfully advanced IDX184 from IND to a proof-of-concept study, while simultaneously advancing two additional HCV discovery programs into IND-enabling preclinical studies," said Jean-Pierre Sommadossi, Ph.D., chief executive officer of Idenix. "As we work to finalize a partnership for our lead HIV drug candidate, our goal in 2009 is to become the first biopharmaceutical company with innovative drugs from three major classes of direct-acting hepatitis C antivirals in clinical development."

The proof-of-concept trial in HCV-infected patients is being conducted at multiple centers around the world. The trial design is a phase I/II, double-blind, placebo-controlled, dose-escalation study to evaluate the safety and antiviral activity of IDX184 in treatment-naive adult patients infected with chronic hepatitis C. The study will evaluate four doses of IDX184, ranging from 25 to 100 mg once-per-day, administered for three days. Each cohort of the study will evaluate ten patients randomized eight to IDX184 and two to placebo.

About IDX184

IDX184 is a once-daily, oral nucleotide prodrug candidate based on Idenix's proprietary li
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
2. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
5. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
6. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
7. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
8. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
9. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Uroplasty, Inc. (NASDAQ: UPI ), a ... innovative proprietary products to treat voiding dysfunctions, today ... quarter ended June 30, 2014.  Global revenue ... grew 19% to $4.1 million, as compared to ... prior year.  Total revenue for the fiscal first ...
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014 /PRNewswire/ ... a leading provider of medication and supply management ... a conference call Thursday, July 31, to discuss ... , Omnicell Second Quarter 2014 earnings conference ... 1:30 p.m. PTWho:  , Randall Lipps, chairman, president ...
(Date:7/24/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, today ... fiscal year 2014 financial results after the market close ... will follow on the same day at 4:30 p.m. ... hosted by Dan Myers , President and Chief ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2Alimera Sciences To Release Second Quarter 2014 Results 2
... WINDSOR, N.J. , July 7 ITelagen, a leading ... it was selected by Zweena, LLC of West Windsor, NJ ... ITelagen, which was selected for its expertise in EHR management, is ... solution. , , , ...
... DENVER , July 7 Invision Sally Jobe ... a new breast ultrasound technology for the early detection of cancer. Screening ... in women with radiologically dense breasts and other risk factors. , ... "Screening breast ultrasound is part ...
Cached Medicine Technology:Zweena Selects ITelagen to Host Personal Health Records Application 2Zweena Selects ITelagen to Host Personal Health Records Application 3Invision Sally Jobe Introduces New Breast Cancer Screening Technology to Denver 2Invision Sally Jobe Introduces New Breast Cancer Screening Technology to Denver 3Invision Sally Jobe Introduces New Breast Cancer Screening Technology to Denver 4
(Date:7/24/2014)... MEMPHIS, Tenn. Researchers at Le Bonheur Children,s Hospital ... results of a clinical trial of a new drug ... illness of healthy adult volunteers intranasally infected with respiratory ... of lower respiratory tract infections in young children in ... comes from the labs of Infectious Disease Specialist John ...
(Date:7/24/2014)... 24, 2014 In signing the ... Obama cited the Atlanta BeltLine Workforce Partnership in ... across the country ( http://www.whitehouse.gov/ready-to-work ). The ... pillar of U.S. economic strategy and profiled successful ... recognition from President Obama highlights the power of ...
(Date:7/24/2014)... with high-throughput data generated by breast cancer biologists ... computational method to determine how gene networks are ... as they respond to potential cancer therapy agents., ... each other in laboratory-grown cells is described in ... PLOS Computational Biology . , The method ...
(Date:7/24/2014)... rare procedure occasionally performed during Jewish circumcisions that involves ... herpes simplex virus type 1 (HSV-1) transmissions documented in ... conducted by Penn Medicine researchers and published online ... Society found. The reviewers, from Penn,s ... in New York, Canada and Israel. , The practiceknown ...
(Date:7/24/2014)... E. Taylor, M.D., director of The Miriam Hospital,s ... 2014 Rhode Island Medical Journal special ... c virus infection (hep c or HCV) is ... address other health challenges, and improve health care ... States, Taylor says, include lack of funding earmarked ...
Breaking Medicine News(10 mins):Health News:RSV research breakthrough to help infected children 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4
... Children who can read and have good phonetic skills - ... may still be poor spellers. In a paper published in ... Annett, at the School of Psychology of Leicester, UK, show ... be right-handed than other poor spellers. , The three-year study ...
... May 29 Alsius Corporation,(Nasdaq: ALUS ... (IVTM(TM)) therapies for critically ill patients, was ... L.P. to provide,intravascular temperature management products to ... the fifth contract we have been awarded ...
... to what is known about relationship between fitness and,diabetes, ... 2 diabetes in women is significantly increased as a ... Index (BMI), and a,combination of the two increases the ... at the 55th Annual Meeting of the American,College of ...
... a first for URAC, the,independent, non-profit accreditation organization ... has developed to help case management,practitioners assess patient ... instrument is a standardized assessment case managers,can voluntarily ... from any interested,parties, including purchasers, policy makers, consumers, ...
... that they have coordinated all the entertainment for Rhinestone ... Hotel Indigo, on,West End, from 7pm until midnight., ... a,place for you to connect with artists, friends and ... the world of country music quick, easy,and free!, ...
... firefighters study to be presented at ... American College of Sports Medicine, MISSOULA, ... Exercise Metabolism (Montana WPEM) will present a human,clinical study at ... that wildland firefighters who consumed a yeast based,(beta glucan) antioxidant ...
Cached Medicine News:Health News:Alsius Corporation Awarded Three-Year Agreement With Premier, Inc. 2Health News:Alsius Corporation Awarded Three-Year Agreement With Premier, Inc. 3Health News:Studies Define Type 2 Diabetes Risk Factors in Women, Adolescents 2Health News:Studies Define Type 2 Diabetes Risk Factors in Women, Adolescents 3Health News:Studies Define Type 2 Diabetes Risk Factors in Women, Adolescents 4Health News:URAC Develops New Case Management Patient Satisfaction Tool, Invites Public Input On Voluntary Survey Instrument 2Health News:URAC Develops New Case Management Patient Satisfaction Tool, Invites Public Input On Voluntary Survey Instrument 3Health News:DigitalRodeo.com Lines Up Entertainment for Rhinestone Cure 2Health News:Montana Center for Work Physiology and Exercise Metabolism Presents Firefighter Health Study 2
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer ... day, 7 days per week. With rugged ... footprint. Powerwave breaks the barrier of traditional ... reliably. One instrument can easily read up ...
Spectra 3000RS & Spectra 3000RSP are very precise instruments. They have a metal base structure, durable parts for long life use, and they are very easy to use and maintain....
... Series Spectrophotometer is truly ... UV-VIS instrumentation. The latest ... into a radically new ... and performance unprecedented in ...
Medicine Products: